allocation must be based on comparative evidence assessment, and we must acknowledge that we lack robust evidence of the population benefits of STH control. We must continue to highlight the comments of de Silva et al., that "lack of evidence to support effectiveness cannot be considered as evidence of ineffectiveness" [8] , but we also need to encourage policymakers to rely on strong evidence of benefit for planning and resource allocation and then work to ensure that we provide clear evidence of these benefits and their true costs.
Part of the challenge of documenting the benefits of deworming results from the types of outcomes we are attempting to measure. When evaluated, some objective endpoints, such as weight gain, do appear to be improved by deworming interventions in children who are documented to be infected [5] . However, as pointed out in many of the criticisms of the interpretation of this evidence, the inclusion of many children without helminth infection dilutes any potential effect size, making it difficult to observe consistent benefit. History has also placed the deworming community in a unique position. Deworming as a public health intervention began long before randomized trials were advocated as the single "gold standard" for evaluating the benefits of health interventions and well in advance of the establishment of the Cochrane Collaboration. As a result, much of the evidence for impact of deworming comes from observational studies. While this observational evidence suggests that deworming children with worms does result in significant health benefits, observational studies are subject to multiple potential sources of bias and may overestimate effect [9] . In addition, although some data from randomized trials of deworming are available, most of these trials have been limited by short follow-up times and have not included sufficient numbers of infected individuals to achieve adequate power to accurately assess outcomes of interest [10] . We should not be surprised by the conclusions of the Cochrane Collaboration. Instead, we should acknowledge the limited number of high-quality studies assessing the impact of deworming and the methodological flaws that result in the conclusions of the Cochrane review [5] .
Many of the outcomes we seek to evaluate are also difficult to ascertain, including markers of early childhood development, such as school performance and cognitive function. These outcomes are also often undervalued in calculations of disease burden [11] . However, there is a global shift toward an improved appreciation of the need to better assess early childhood development as a critical component of disease burden and of interventional impact. As the global community moves toward the Sustainable Development Goals, child development is increasingly being recognized as fundamental to addressing inequities and ensuring the right of every individual to realize their true potential [12, 13] . This is a moment in which we, as a community deeply concerned about the negative impact of STH on growth, cognition, and educational attainment, can help to better define the metrics needed to evaluate early childhood development and to measure and document the positive impacts of deworming on these outcomes.
The scientific debate that has resulted from the controversy surrounding the benefits of deworming is healthy and should be encouraged. We should redirect the passion and energy away from unproductive criticism and toward solutions that will ultimately serve our community best. We should not argue that evidence for benefit from deworming should be judged by different criteria than other public health interventions. This is a moment of truly unique opportunity for the STH community. Let us come together to better define, design, demonstrate, and deliver the evidence needed to document the important gains provided by deworming.
